{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264631","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.746544+00:00","generated_at":"2026-05-17T00:42:10.567728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biomea Q3 net loss $16.4M (down 50% YoY); cash $47M; advances icovamenib and BMF-650","bullets":["Net loss $16.4M for Q3 2025 vs $32.8M in Q3 2024; R&D expenses down ~47% YoY.","Cash, cash equivalents $47M as of Sep 30, 2025; raised ~$68M in two public offerings extending runway into Q1 2027.","Icovamenib Phase II COVALENT-111: 1.5% mean HbA1c reduction at Week 52 in severe insulin-deficient T2D patients (p=0.01).","BMF-650 (oral GLP-1 RA) dosed first patient in Phase I; 28-day weight reduction data expected H1 2026.","Workforce reduced to ~40 employees as part of operational streamlining."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264631","json":"https://secwatch.observer/filing/0001193125-25-264631.json","markdown":"https://secwatch.observer/filing/0001193125-25-264631.md","text":"https://secwatch.observer/filing/0001193125-25-264631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/0001193125-25-264631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/bmea-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:42:10.567728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}